Case series shows adjunctive benefits of TLR-3-activated MSCs in treating synovial sepsis, suggesting new therapeutic options.
Because of the increasing emergence of AMR infections in both veterinary species and humans, the advancement of alternative and synergistic therapeutics is imperative. This case series highlights the use of TLR-3-activated CB-MSCs as an adjunctive treatment in cases of synovial sepsis involving chronic or AMR infections.
No takes yet. Share an insight, caveat, or question.
Barton et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: